• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor.利用自抑制激酶的疏水模体实现新型蛋白激酶抑制模式:成纤维细胞生长因子受体的非 ATP 依赖性抑制剂的发现。
J Biol Chem. 2011 Jun 10;286(23):20677-87. doi: 10.1074/jbc.M110.213736. Epub 2011 Mar 24.
2
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.能够克服对第一代FGFR激酶抑制剂耐药性的共价抑制剂的研发。
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4869-77. doi: 10.1073/pnas.1403438111. Epub 2014 Oct 27.
3
Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening.基于结构的虚拟筛选发现新型成纤维细胞生长因子受体 1 激酶抑制剂。
J Med Chem. 2010 Feb 25;53(4):1662-72. doi: 10.1021/jm901386e.
4
Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation.LADD综合征中FGFR2活性降低的结构基础:对FGFR自身抑制和激活的影响
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19802-7. doi: 10.1073/pnas.0709905104. Epub 2007 Dec 3.
5
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.TAS-120 克服 FGFR2 融合阳性肝内胆管癌患者对 ATP 竞争性 FGFR 抑制剂的耐药性。
Cancer Discov. 2019 Aug;9(8):1064-1079. doi: 10.1158/2159-8290.CD-19-0182. Epub 2019 May 20.
6
Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state.守门基因突变通过破坏自身抑制状态激活 FGFR 酪氨酸激酶。
Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2213090120. doi: 10.1073/pnas.2213090120. Epub 2023 Feb 15.
7
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.发现培米替尼:一种强效和选择性成纤维细胞生长因子受体(FGFR)抑制剂。
J Med Chem. 2021 Aug 12;64(15):10666-10679. doi: 10.1021/acs.jmedchem.1c00713. Epub 2021 Jul 16.
8
Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.淋巴细胞特异性激酶Lck与非选择性和Src家族选择性激酶抑制剂复合物的结构分析
Structure. 1999 Jun 15;7(6):651-61. doi: 10.1016/s0969-2126(99)80086-0.
9
2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.2-氧代-3,4-二氢嘧啶并[4,5-d]嘧啶衍生物作为新型不可逆泛成纤维细胞生长因子受体(FGFR)抑制剂。
Eur J Med Chem. 2017 Jul 28;135:531-543. doi: 10.1016/j.ejmech.2017.04.049. Epub 2017 Apr 22.
10
Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase Cγ.两个成纤维细胞生长因子受体激酶分子协同作用以募集并使磷脂酶Cγ发生磷酸化。
Mol Cell. 2016 Jan 7;61(1):98-110. doi: 10.1016/j.molcel.2015.11.010. Epub 2015 Dec 10.

引用本文的文献

1
Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma.肝内胆管癌新兴分子靶向治疗的最新进展
RSC Med Chem. 2025 Feb 6. doi: 10.1039/d4md00881b.
2
Fibroblast growth factor receptor fusions in cancer: opportunities and challenges.成纤维细胞生长因子受体融合在癌症中的作用:机遇与挑战。
J Exp Clin Cancer Res. 2021 Nov 3;40(1):345. doi: 10.1186/s13046-021-02156-6.
3
Design and Synthesis of Novel Nordihydroguaiaretic Acid (NDGA) Analogues as Potential FGFR1 Kinase Inhibitors With Anti-Gastric Activity and Chemosensitizing Effect.新型去甲二氢愈创木酸(NDGA)类似物的设计与合成:作为具有抗胃癌活性和化学增敏作用的潜在FGFR1激酶抑制剂
Front Pharmacol. 2020 Sep 11;11:518068. doi: 10.3389/fphar.2020.518068. eCollection 2020.
4
Inhibition of Oncogenic Kinases: An In Vitro Validated Computational Approach Identified Potential Multi-Target Anticancer Compounds.抑制致癌激酶:经体外验证的计算方法鉴定出潜在的多靶标抗癌化合物。
Biomolecules. 2019 Mar 28;9(4):124. doi: 10.3390/biom9040124.
5
FGFR2 regulation by picrasidine Q inhibits the cell growth and induces apoptosis in esophageal squamous cell carcinoma.皮拉菌素 Q 通过调控 FGFR2 抑制食管鳞癌细胞生长并诱导其凋亡。
J Cell Biochem. 2018 Feb;119(2):2231-2239. doi: 10.1002/jcb.26385. Epub 2017 Oct 27.
6
Conformational Control of UDP-Galactopyranose Mutase Inhibition.UDP-吡喃半乳糖变位酶抑制作用的构象控制
Biochemistry. 2017 Aug 1;56(30):3983-3992. doi: 10.1021/acs.biochem.7b00189. Epub 2017 Jul 20.
7
Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases.成纤维细胞生长因子受体酪氨酸激酶中四位点变构网络的解析
Elife. 2017 Feb 6;6:e21137. doi: 10.7554/eLife.21137.
8
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation.ARQ 087的临床前活性,一种靶向FGFR失调的新型抑制剂
PLoS One. 2016 Sep 14;11(9):e0162594. doi: 10.1371/journal.pone.0162594. eCollection 2016.
9
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.来自替凡替尼随机II期研究的二线肝细胞癌患者的肿瘤和循环生物标志物
Oncotarget. 2016 Nov 8;7(45):72622-72633. doi: 10.18632/oncotarget.11621.
10
Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.采用经过验证的、适用于临床的免疫测定法检测MET/HGF受体对小分子酪氨酸激酶抑制剂的药效学反应。
Clin Cancer Res. 2016 Jul 15;22(14):3683-94. doi: 10.1158/1078-0432.CCR-15-2323. Epub 2016 Mar 21.

本文引用的文献

1
Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197.发现一种新型的蛋白激酶抑制模式,其特征在于通过 ARQ 197 抑制人间质上皮转化因子 (c-Met) 蛋白自身磷酸化的抑制机制。
J Biol Chem. 2011 Jun 10;286(23):20666-76. doi: 10.1074/jbc.M110.213801. Epub 2011 Mar 24.
2
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.小分子激酶抑制剂的激活状态依赖性结合:来自生物化学的结构见解
Chem Biol. 2010 Nov 24;17(11):1241-9. doi: 10.1016/j.chembiol.2010.09.010.
3
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.ARQ 197,一种新型、选择性的人 c-Met 受体酪氨酸激酶抑制剂,具有抗肿瘤活性。
Mol Cancer Ther. 2010 Jun;9(6):1544-53. doi: 10.1158/1535-7163.MCT-09-1173. Epub 2010 May 18.
4
Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells.在活细胞中,成纤维细胞生长因子受体的酪氨酸自身磷酸化需要不对称的受体接触。
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2866-71. doi: 10.1073/pnas.0914157107. Epub 2010 Jan 26.
5
Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening.基于结构的虚拟筛选发现新型成纤维细胞生长因子受体 1 激酶抑制剂。
J Med Chem. 2010 Feb 25;53(4):1662-72. doi: 10.1021/jm901386e.
6
Fibroblast growth factor signalling: from development to cancer.成纤维细胞生长因子信号通路:从发育到癌症。
Nat Rev Cancer. 2010 Feb;10(2):116-29. doi: 10.1038/nrc2780.
7
An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7 kinase is released through binding of Nek9.细胞周期调控的Nek7激酶中的一个自抑制酪氨酸基序通过与Nek9结合而被释放。
Mol Cell. 2009 Nov 25;36(4):560-70. doi: 10.1016/j.molcel.2009.09.038.
8
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.马替尼(AB1010),一种针对 KIT 的有效且选择性的酪氨酸激酶抑制剂。
PLoS One. 2009 Sep 30;4(9):e7258. doi: 10.1371/journal.pone.0007258.
9
Protein kinase inhibitors: contributions from structure to clinical compounds.蛋白激酶抑制剂:从结构到临床化合物的贡献
Q Rev Biophys. 2009 Feb;42(1):1-40. doi: 10.1017/S0033583508004745. Epub 2009 Mar 19.
10
The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations.成纤维细胞生长因子(FGF)受体自身磷酸化的精确序列受动力学驱动,并被致癌突变破坏。
Sci Signal. 2009 Feb 17;2(58):ra6. doi: 10.1126/scisignal.2000021.

利用自抑制激酶的疏水模体实现新型蛋白激酶抑制模式:成纤维细胞生长因子受体的非 ATP 依赖性抑制剂的发现。

A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor.

机构信息

ArQule, Inc, Woburn, Massachusetts 01801, USA.

出版信息

J Biol Chem. 2011 Jun 10;286(23):20677-87. doi: 10.1074/jbc.M110.213736. Epub 2011 Mar 24.

DOI:10.1074/jbc.M110.213736
PMID:21454610
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3121527/
Abstract

Protein kinase inhibitors with enhanced selectivity can be designed by optimizing binding interactions with less conserved inactive conformations because such inhibitors will be less likely to compete with ATP for binding and therefore may be less impacted by high intracellular concentrations of ATP. Analysis of the ATP-binding cleft in a number of inactive protein kinases, particularly in the autoinhibited conformation, led to the identification of a previously undisclosed non-polar region in this cleft. This ATP-incompatible hydrophobic region is distinct from the previously characterized hydrophobic allosteric back pocket, as well as the main pocket. Generalized hypothetical models of inactive kinases were constructed and, for the work described here, we selected the fibroblast growth factor receptor (FGFR) tyrosine kinase family as a case study. Initial optimization of a FGFR2 inhibitor identified from a library of commercial compounds was guided using structural information from the model. We describe the inhibitory characteristics of this compound in biophysical, biochemical, and cell-based assays, and have characterized the binding mode using x-ray crystallographic studies. The results demonstrate, as expected, that these inhibitors prevent activation of the autoinhibited conformation, retain full inhibitory potency in the presence of physiological concentrations of ATP, and have favorable inhibitory activity in cancer cells. Given the widespread regulation of kinases by autoinhibitory mechanisms, the approach described herein provides a new paradigm for the discovery of inhibitors by targeting inactive conformations of protein kinases.

摘要

通过优化与不太保守的非活性构象的结合相互作用,可以设计出具有增强选择性的蛋白激酶抑制剂,因为此类抑制剂不太可能与 ATP 竞争结合,因此不太可能受到细胞内高浓度 ATP 的影响。对许多无活性蛋白激酶(尤其是自动抑制构象中的)的 ATP 结合裂隙进行分析,导致在该裂隙中鉴定出一个以前未披露的非极性区域。该 ATP 不兼容的疏水区与先前表征的疏水性变构后袋以及主口袋不同。构建了无活性激酶的通用假设模型,并且在本文所描述的工作中,我们选择成纤维细胞生长因子受体(FGFR)酪氨酸激酶家族作为案例研究。使用模型的结构信息来指导从商业化合物文库中筛选出的 FGFR2 抑制剂的初步优化。我们描述了该化合物在生物物理、生化和基于细胞的测定中的抑制特性,并使用 X 射线晶体学研究表征了其结合模式。结果如预期所示,这些抑制剂可防止自动抑制构象的激活,在存在生理浓度的 ATP 时保留完全抑制效力,并且在癌细胞中具有良好的抑制活性。鉴于激酶的广泛自动抑制机制调节,本文所述的方法为通过靶向蛋白激酶的非活性构象来发现抑制剂提供了新的范例。